Currently, PD-1/PD-L1 inhibitors have been approved for the treatment of various tumors, including NSCLC, melanoma, urothelial cancer, esophageal cancer, RCC, and Hodgkin's lymphoma (55, 56, 66–75). Here, CD274 is linked to melanoma.